**BenevolentAI**
("BenevolentAI" or the "Company" or the "Group")

**Directorate Change**

**London, UK, 21 September 2023:** BenevolentAI (Euronext Amsterdam: BAI), a leader in the development of advanced AI that accelerates biopharma discovery, announces that Joanna Shields has decided to step down as Chief Executive Officer (CEO) and executive Board member to pursue other endeavours but will continue to support the Board and the Company as a strategic adviser.

The Board has initiated a search for her replacement.

Dr. François Nader, Chair of the Board of Directors, will today also assume the role of Acting Chief Executive Officer (Acting CEO) until a successor is appointed. Jean Raby, Senior Independent Director, will work closely with Dr. Nader to provide support during this period.

**Dr François Nader, Chair and Acting CEO of BenevolentAI, commented:**
*"On behalf of the Board and the entire team at BenevolentAI, I want to extend our thanks to Joanna for her transformative five years as CEO. Under her leadership, BenevolentAI has become a leader in AI-augmented drug discovery and achieved significant commercial and development milestones.*

*"BenevolentAI is committed to a growth strategy focused on expanding end-to-end drug discovery partnerships with pharma and biotechnology companies, developing our own pipeline of drug candidates, and providing life sciences companies with a suite of AI knowledge exploration tools that leverage our unique AI platform."*

**Joanna Shields, Chief Executive Officer of BenevolentAI, commented:**
*"I am immensely proud of the achievements of the exceptional team at BenevolentAI. Today, our AI-powered discovery platform has produced a strong portfolio of differentiated drug programmes, and our end-to-end discovery technology platform alongside our cutting-edge knowledge exploration tools are poised for commercial adoption. I eagerly anticipate what lies ahead for the Company, and as an adviser, I am looking forward to supporting the Company to achieve even greater success in the future."*

**Enquiries:**

**Investors:**
Fleur Wood – VP Investor Relations
fleur.wood@benevolent.ai
investors@benevolent.ai
T: +44(0) 203 781 9360

**Media:**
Rajin Kang - VP Communications
rajin.kang@benevolent.ai
T: +44(0) 203 781 9360

**FTI Consulting:**
Ben Atwell/Simon Conway/Victoria Foster Mitchell
T: +44 203 727 1000
BenevolentAI@fticonsulting.com

**About BenevolentAI**

BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of this AI platform, its scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform™ powers the Company's in-house drug pipeline and supports successful collaborations with AstraZeneca, as well as leading research and charitable institutions.

**Benevolent**<sup>AI</sup>

**Forward-looking Statements**